Keyphrases
Placebo
87%
Gastrointestinal Bleeding
83%
Network Meta-analysis
83%
Randomized Controlled Trial
83%
ICU Patients
83%
Joint Destruction
83%
Heterogeneous Treatment Effects
83%
Analysis Protocol
83%
TNF Inhibitors
83%
Tumour Necrosis Factor Inhibitor (TNFi)
83%
Biosimilar
83%
Stress Effect
83%
Stress Ulcer Prophylaxis
83%
Rheumatoid Arthritis
83%
Methotrexate
66%
Intensive Care Unit
62%
Golimumab
50%
Number of Risk Factors
41%
Patients at Risk
41%
Simplified Acute Physiology Score II
41%
Pantoprazole
41%
Certolizumab
33%
Adalimumab
33%
Infliximab
33%
Placebo-controlled
33%
Etanercept
33%
Posterior Probability Distribution
20%
Protocol Analysis
20%
Adult ICU
20%
Continuous Scale
20%
Bayesian Hierarchical Model
20%
Marginal Effects
20%
Statistical Analysis Plan
20%
Clinically Significant
20%
Disease Severity
20%
Credible Interval
20%
Subgroup Analysis
20%
90-day Mortality
20%
Once-daily
20%
Treatment Effect
20%
Inhibitory Effect
16%
Monotherapy
16%
Bayesian Analysis
16%
Enbrel
16%
Remicade
16%
High Dose
16%
Medicine and Dentistry
Placebo
100%
Stress Ulcer
83%
Network Meta-Analysis
83%
Rheumatoid Arthritis
83%
Joint Destruction
83%
TNF Inhibitor
83%
Inflammatory Arthritis
83%
Treatment Effect
83%
Randomized Controlled Trial
83%
Biosimilar
83%
Gastrointestinal Bleeding
66%
Methotrexate
55%
Intensive Care Unit
50%
Golimumab
41%
Etanercept
41%
Infliximab
41%
Pantoprazole
33%
SAPS II
33%
Adalimumab
27%
Post-Hoc Analysis
16%
Diseases
16%
Subgroup Analysis
16%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Arthritis
83%
Tumor Necrosis Factor Inhibitor
83%
Biosimilar Agent
83%
Joint Destruction
83%
Placebo
83%
Randomized Controlled Trial
83%
Rheumatoid Arthritis
83%
Methotrexate
55%
Etanercept
41%
Infliximab
41%
Golimumab
41%
Adalimumab
27%
